Sponsors of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for cancer can now request approval for intravenous dosing regimens that weren’t included in the pivotal trials or earlier developmental studies, the FDA said in a final guidance released yesterday.
Source: Drug Industry Daily